KRSNAA

Krsnaa Diagnostics share price & results

Krsnaa Diagnostics Limited· Healthcare

One of India's largest diagnostic chains, running radiology, pathology and tele-radiology centres mostly under government PPP contracts.

₹518.7 +0.61%
MCap ₹1.5k Cr Price to earnings (TTM to Sept 2026) 15.57× Return on equity (TTM to Sept 2026) 9.54%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day KRSNAA alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
KRSNAA at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

1 of 5 judged targets kept · 15 open · verdicts reflect calls analysed to Q2 FY27.

Krsnaa Diagnostics Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (1 achieved, 4 missed, 15 open).

Watch execution in Growth & Demand (1 achieved · 1 delayed/missed) · Operations & Margins (1 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Growth Retail Revenue Share
5% to 8% in FY26
Q4 FY25
Q2 FY27:Promise deadline has passed.
Achieved
Growth FY25 Revenue Growth
25% YoY growth for FY25
Q3 FY25
Q2 FY27:Promise deadline has passed.
Missed
Operations Retail Segment Profitability
Breakeven by the end of FY26
Q1 FY26
Q2 FY27:Achieved operational breakeven in September 2026, but full absolute breakeven pushed to Q3/early Q4 FY27, exiting FY27 with positive EBITDA.
Delayed

Source: Inve Guidance Tracker for Krsnaa Diagnostics Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Krsnaa Diagnostics Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 3 Nov 2026

Q2 FY27: Krsnaa Diagnostics Limited Q2 FY27

Krsnaa Diagnostics delivered strong operational revenue growth of 32% YoY in Q2 FY27 to ₹271 crores and crossed ₹500 crores in half-yearly revenue for the first time (₹507 crores in H1 FY27). Profitability saw slight margin compression to 27% EBITDA margin and PAT of ₹25 crores due to upfront operating costs and manpower scaling for new projects, notably Rajasthan. A central focus for investors was the elevated receivables balance of ₹470 crores, against which management expects collections of approximately ₹200 crores in Q3 FY27 as state disbursements resume.

What management highlighted

  • Revenue from operations grew 32% YoY to ₹271 crores in Q2 FY27 and 27% YoY to ₹507 crores in H1 FY27
  • Retail segment generated ₹23.5 crores in Q2 FY27, up ~35% YoY, with patient volume up 45% and test volume up 48%
  • Promoter group demonstrated confidence through allotment of convertible warrants of ₹92 crores (₹23 crores already contributed)

Source: Inve analysis of Krsnaa Diagnostics Limited’s Q2 FY27 earnings call · to 3 Nov 2026

Compare across 8 analysed calls

Price & Snapshot

₹518.7 +0.61% · +₹3.15

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance −35.7% 1Y

₹500₹600₹700₹800Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 14 Aug 2026Q2 FY27 — 3 Nov 2026

1Y: ₹806.2 on 14 Nov 2025 → ₹518.7. High ₹826.8 (17 Nov 2025), low ₹475 (6 Nov 2026).

Previous close
₹515.55
Market cap
₹1.5k Cr
52-week range
₹475 – ₹826.8
One year
−37.26%
Price to earnings (TTM to Sept 2026)
15.57×
Return on equity (TTM to Sept 2026)
9.54%

Reported

Key financial metrics & valuation ratios

Revenue: 31.0 ₹ crore (+1450.0% YoY) · Net profit: 25.0 ₹ crore (+8.7% YoY) · Return on equity: 9.54 % (+2.3 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue31.0 ₹ crore+1450.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin30.0 %−2.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit25.0 ₹ crore+8.7% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity9.54 %+2.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-9.31 %−5.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.92 %−7.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Counterparties named by Krsnaa Diagnostics Limited

  • Krsnaa Diagnostics Limited → acquires or invests in → Apulki Healthcare

    Acquires / invests · Closed / completed · Q4 FY26

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:KRSNAA
Exchange
NSE
Currency
INR

What Krsnaa Diagnostics Limited does

Sourced to annual report & earnings calls.

Krsnaa Diagnostics operates a hub-and-spoke network of radiology (CT/MRI/X-ray), pathology and tele-radiology services across India, largely through Public-Private Partnership (PPP) contracts with government hospitals and health centres alongside a retail diagnostics arm. It earns by running these centres under long-tenure PPP contracts (radiology tenures average around 10+ years, pathology around 5+ years) and through a growing retail patient business (RPL) offering wellness packages, home collection and preventive health screening. The company also runs one of India's largest NABH-accredited tele-radiology reporting hubs, remotely reporting X-ray, CT and MRI scans for patients in remote locations.

Segments

  • Radiology
  • Pathology
  • Tele-radiology
  • Retail Diagnostics (RPL)
CT/MRI centres
190 (target 200+)
Pathology labs
147 (target 290+)
Patient collection centres
4,700+ (target 5,000+)
States/UTs presence
18
Districts presence (PAN India)
331
Patients served in last 5 years
68 million+

How the price took the results

Moved an average of ±2.4% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY273 Nov 2631 25+1450.0%₹498.7 → ₹485.8−2.6%
Q1 FY2714 Aug 2620 16+150.0%₹556.75 → ₹575.3+3.3%
Q4 FY2626 May 26-1 43−110.0%₹553.85 → ₹548.95−0.9%
Q3 FY266 Feb 26-3 16−133.3%₹720.7 → ₹700.8−2.8%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Krsnaa Diagnostics Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Krsnaa Diagnostics Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Quick Answers

Frequently asked questions on Krsnaa Diagnostics Limited

Compiled directly from KRSNAA's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Krsnaa Diagnostics Limited (KRSNAA) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Krsnaa Diagnostics Limited reported revenue of ₹31 Cr, net profit of ₹25 Cr, an operating margin of 30.0%. Diluted earnings per share stood at ₹7.81.

How is Krsnaa Diagnostics Limited (KRSNAA) valued today, and what growth does the stock price imply?

Krsnaa Diagnostics Limited (KRSNAA) trades at ₹518.7, with a market capitalization of ₹1.5k Cr, a trailing P/E multiple of 15.57×, return on equity (ROE) of 10.84%, ROCE of 12.62%.

Did Krsnaa Diagnostics Limited (KRSNAA) management keep or miss its earnings call guidance?

Across 20 management guidance targets tracked from Krsnaa Diagnostics Limited's earnings calls, 1 was achieved, 4 missed, and 15 remain open (20% delivered among resolved targets). Sampled guidance includes Retail Revenue Share: "5% to 8% in FY26" (stated in Q4 FY25, current status: achieved).

Who owns Krsnaa Diagnostics Limited (KRSNAA) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 27.1%, FIIs hold 3.8%, DIIs hold 14.5%, Public shareholders hold 54.5%.

What did Krsnaa Diagnostics Limited (KRSNAA) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Nov 2026) concall, Krsnaa Diagnostics delivered strong operational revenue growth of 32% YoY in Q2 FY27 to ₹271 crores and crossed ₹500 crores in half-yearly revenue for the first time (₹507 crores in H1 FY27). Profitability saw slight margin compression to 27% EBITDA margin and PAT of ₹25 crores due to upfront operating costs and manpower scaling for new projects, notably Rajasthan. A central focus for investors was the elevated receivables balance of ₹470 crores, against which management expects collections of approximately ₹200 crores in Q3 FY27 as state disbursements resume. Read Krsnaa Diagnostics Limited Q2 FY27 concall summary →